Your donation will make a difference:
Cystic Fibrosis Trust

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Gastro-oesphageal reflux in patients with cystic fibrosis and its effect on lung function

Details

Therapeutic category
the type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise

Other

Trial status

Open to recruitment

Full title

Gastro-oesphageal reflux in patients with cystic fibrosis and its effect on lung function: an observational study

Gastro - oesophageal reflux disease(GORD) is a condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet) It is common in patient with Cystic Fibrosis. Although symptoms such as heartburn and acid taste in the mouth can occur, often there are no symptoms. Studies have suggested a link between a worsening lung function and the amount of GORD. A potential mechanism is by the stomach content travelling into the lungs causing inflammation and altering the usual organisms that are present. If that is the case, there may be opportunities for new drugs and /or surgical procedures. The aim of this observational study is to investigate if GORD affects the lung function. The study will assess mircobiology and presence of markers of reflux aspiration. These are substances that are found in the gastrointrestinal tract and that , if detected in sputum, support the presence of stomach contents in the lungs. In addition factors that may influence GORD such as antacids tablets and enteral feeding ( via a tube into the stomach) will be evaluated. GORD will be measured by using special probes that assess the function of the oesophagus, PH (acidity) and presence of gastic contents within the gullet. The participants will provide measures of lung function, clinical details, blood, and sputum samples as well as complete symptoms questionnaires

Trial type

Non-medication

Length of participation
the length of time a participant will take part in a trial, from the first to the last appointment

24 hours

Last edited date

18 December 2017

CF sponsor

University Hospital South Manchester

CF sponsor type

Academic

Who can take part?

Age

18+

Top inclusion criteria
  • Confirmed diagnosis of Cystic Fibrosis
Top exclusion criteria
  • Pregnant
  • Previous fundoplication
  • Clinically unstable

CF centres running this trial

Closed

University Hospital of South Manchester NHS Foundation Trust

Address

Wythenshawe Hospital Southmoor Road Wythenshawe Manchester Greater Manchester M23 9LT

Recruitment starts

August 2018

Contact

,

Get in touch